Effect of a Digital Therapeutic on Processing Speed in Adults With Multiple Sclerosis
Phase: NA
Conditions: Multiple Sclerosis, Cognitive Decline
Sponsor: University of California, San Francisco

Digital Cognition in Multiple Sclerosis (DigCog)
NCT03569618
August 1st, 2018

CONFIDENTIAL  | 
Key Aims
• Feasibility replication
• Identiﬁcation of predictors of successful completion
• Evaluate superiority to active control
Study Design
!2
Daily AKL-T09
Daily AKL-T03
Day 0
Screening/
Baseline
Subject 
Recruitment
2 Groups 
• MS/CIS - AKL-T03
• MS/CIS - AKL-T09
Key Outcomes
1o SDMT
2o Durability 8 weeks post completion
-   Exploratory: other cognitive and mood
-   Compliance
Key Screening Measures
• Range SDMT Z score [-2 to 0
• Depression: none or mild (moderate or
severe excluded based on self- or doctor
report)
• Have WiFi at home
• Vision 20/50 OU or better
Day 98
Day 42
No Intervention
Durability of effects